Randomized Controlled Study Comparing Use of Propofol Plus Fentanyl versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients with Advanced Liver Disease by Sameh Abdelkhalik Ahmed, Amal Selim, Nehad Hawash, Ahmed Khaled Tawfik, Mohamed Yousef, Abdelrahman Kobtan, Rehab Badawi, Sally Elnawasany, Reham Abdelkader Elkhouly, Amr Shaaban Hanafy, Fatma H. Rizk, Loai Mansour, Sherief Abd-Elsalam

“…We aimed to investigate the safety and efficacy of propofol plus fentanyl versus midazolam plus fentanyl as sedative for patients with advanced liver disease presented for gastrointestinal endoscopy. …”
Get full text

Effects of Resveratrol on Liver Function Tests in Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis of Randomized Controlled Trials by P. Ebrahimpour, M. Karamian, A. Sharifi

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

The association between serum fructosamine and random spot urine fructose levels with the severity of non-alcoholic fatty liver disease – an analytical cross-sectional study by H Kamuzinzi, M Kgomo, P Rheeder, N Dada, P Bester

“…Non-alcoholic fatty liver disease (NAFLD) in South Africa and Africa at large is considered a hidden threat. …”
Get full text

Association between the atherogenic index of plasma and non-alcoholic fatty liver disease in Korean pregnant women: secondary analysis of a prospective cohort study by Rong Shuai, Yuxing He, Dongqian Yang, Yingying Zhang, Li Zhang

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis by Wu X, Pan T, Fang Z, Hui T, Yu X, Liu C, Guo Z, Liu C

Subjects: “…metabolic dysfunction-associated steatotic liver disease…”
Get full text

The feasibility of using liver function indices and FibroScan in combination to predict the occurrence of anti-tuberculosis drug-induced liver injury in Patients with liver disease by Shaoqiang Wu, Qiaohua Yang, Huai Li, Yongzhong Li

Subjects: Get full text

Asymptomatic elevation of serum aminotransferase activity: stages of diagnostic search by Yu. A. Tereshchenko, S. Yu. Tereshchenko

Subjects: Get full text

Serum IgG level in autoimmune liver diseases and its significance: Is there a need to revisit existing criteria? Experience from a tertiary care center by Annapoorani Varadarajan, Archana Rastogi, Rakhi Maiwall, Chaggan Bihari, Sherin Thomas, Saggere Muralikrishna Shasthry

Subjects: Get full text

Progress in research of nursing practice patterns for patients with nonalcoholic fatty liver disease (非酒精性脂肪肝护理模式的研究进展) by GENG Yuexiao (耿钥潇), MA Jingyi (马靖沂), LI Sha (李沙), LU Xiaoman (卢晓曼)

Subjects: “…nonalcoholic fatty liver disease…”
Get full text

Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study by Atsushi Nakajima, Yasushi Honda, Kento Imajo, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Asako Nogami, Satoru Saito, Michihiro Iwaki, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Noritoshi Kobayashi

“…Introduction Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome phenotype in the liver and thus obviously associated with metabolic abnormalities, including insulin resistance-related to hyperglycaemic and hyperlipidaemia. …”
Get full text

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study by Hui Liu, Mingming Deng, Gang Luo, Jie Chen

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Hepatokine leukocyte cell‐derived chemotaxin 2 as a biomarker of insulin resistance, liver enzymes, and metabolic dysfunction‐associated steatotic liver disease in the general population by Keita Suzuki, Hiromasa Tsujiguchi, Akinori Hara, Yumie Takeshita, Hisanori Goto, Yujiro Nakano, Reina Yamamoto, Hiroaki Takayama, Atsushi Tajima, Tatsuya Yamashita, Masao Honda, Hiroyuki Nakamura, Toshinari Takamura

“…Since LECT2 is up‐regulated by the inactivation of the energy sensor AMPK in the liver, we hypothesized that LECT2 has potential as a biomarker for metabolic dysfunction‐associated steatotic liver disease (MASLD). Therefore, we investigated whether circulating LECT2 levels are associated with insulin sensitivity, liver enzymes, and MASLD. …”
Get full text

Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis by Marcello Dallio, Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Paolo Vaia, Giorgia Iadanza, Simone Olivieri, Annachiara Coppola, Marco Niosi, Alessandro Federico

“…Abstract Background Dysgeusia is a distortion of the sense of taste whose prevalence and relationship with nutritional status in Metabolic dysfunction-associated Steatotic Liver Disease (MASLD)-related advanced chronic liver disease (ACLD) have never been systematically explored. …”
Get full text

Targeting Liver Biopsies For Optimal Biopsy Site In Diffused Liver Disease Using Real-Time Shear Wave Elastography: A Prospective, Single Center Study by Naushaba Malik, Shahbakht Aftab, Rida Noor, Noor Aftab, Rizwan, Rehan

“…Conclusions: This study compared a new sound wave technique (SWE) to a traditional method (TE) for diagnosing liver scarring (fibrosis) in people with chronic liver disease.  The findings suggest that the new technique is just as accurate as the traditional one for diagnosing moderate and severe scarring stages. …”
Get full text

Research of <i>PNPLA3</i> I148M Gene Polymorphism in Patients with Non-Alcoholic Fatty Liver Disease, with Liver Cirrhosis and with Hepatocellular Carcinoma by V. V. Petkau, G. A. Tsaur, E. N. Bessonova, A. A. Karimova

“…Aim: to determine the frequency of PNPLA3 rs738409 C&gt;G gene polymorphism, leading to p.I148M substitution, in patients with non-alcoholic fatty liver disease (NAFLD), and to reveal the association between polymorphism and probable NAFLD outcomes: liver cirrhosis (LC) and hepatocellular carcinoma (HCC).Materials and methods. …”
Get full text

Association between the composite dietary antioxidant index and non-alcoholic fatty liver disease: evidence from National Health and Nutrition Examination Survey 2005–2016 by Yidian Fu, Yidian Fu, Chao Jiang, Zonglin Li, Xiangyun Shi, Peiyuan Lv, Peiyuan Lv, Jingbo Zhang

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Association between neutrophil-albumin ratio and ultrasound-defined metabolic dysfunction-associated fatty liver disease in U.S. adults: evidence from NHANES 2017–2018 by Ming-yu He, Xin-jie Du, Yi-ming Liu

Subjects: “…Metabolic dysfunction-associated fatty liver disease…”
Get full text

Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis by Waseem Amjad, Adnan Malik, Waqas Qureshi, Brittany Dennis, Mirrah Mumtaz, Rabbia Haider, Shakeel Jamal, Faisal Jaura, Aijaz Ahmed

Subjects: “…non-alcoholic fatty liver disease…”
Get full text

Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States by Fan Zhang, Longgen Liu, Wenjian Li

Subjects: “…Metabolic dysfunction-associated steatotic liver disease…”
Get full text

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study by Syed Mushfiq, Ghulam Nabi Yatoo, Bilal Ahmad Mir, Zubaida Rasool

“…Background and Aim: Non-alcohol fatty liver disease (NAFLD) is a metabolic disorder that represents the hepatic manifestation of systemic process, and is a strong risk factor for diabetes Meletus, whereas the presence of DM increases the severity of NAFLD/NASH and its progression. …”
Get full text